Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression
Molecules · 2024
DOI: 10.3390/molecules29143379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Yusuke Kito und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Cell Proliferation, Receptors, Leukotriene, Leukotriene Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a cancer with a poor prognosis due to difficulties in diagnosis and limited treatment options, highlighting the urgent need for new targeted therapies. In a clinical setting, we found that leukotriene levels in bile were higher than in serum. Immunohistochemical analysis of surgically resected samples also revealed that CysLT receptor 1 (CysLTR1) was more highly expressed in CCA than in normal bile duct tissue, prompting us to investigate leukotriene as a potential therapeutic target in CCA. In vitro studies using CCA cell lines expressing CysLTR1 showed that leukotriene D4, a major ligand of CysLTR1, promoted cell proliferation, with increased phosphorylation of AKT and extracellular signal-regulated kinase 1/2 (ERK1/2). Additionally, treatment with two clinically available anti-allergic drugs—zileuton, an inhibitor of CysLT formation, and montelukast, a CysLTR1 inhibitor—had inhibitory effects on cell proliferation and migratory capacity, accompanied by the reduced phosphorylation of AKT and ERK1/2. Furthermore, the simultaneous administration of both drugs synergistically enhanced the inhibitory effect on cell proliferation. Our study suggests that use of these drugs may represent a novel approach to treat CCA through drug repositioning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.
- Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi 507-8522, Japan.
ORCID-Profile: Yusuke Kito, Michihiro Yoshida, Yasuki Hori, Akihisa Kato, Hidenori Sahashi, Hiromi Kataoka
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kito, Y., Kachi, K., Yoshida, M., Hori, Y., Kato, A., Sahashi, H., Toyohara, T., Kuno, K., Adachi, A., Urakabe, K., & Kataoka, H. (2024). Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression. Molecules. https://doi.org/10.3390/molecules29143379
Vancouver
Kito Y, Kachi K, Yoshida M, Hori Y, Kato A, Sahashi H, et al. Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression. Molecules. 2024. doi:10.3390/molecules29143379
BibTeX
@article{Kito2024,
author = {Kito, Yusuke and Kachi, Kenta and Yoshida, Michihiro and Hori, Yasuki and Kato, Akihisa and Sahashi, Hidenori and Toyohara, Tadashi and Kuno, Kayoko and Adachi, Akihisa and Urakabe, Kenji and Kataoka, Hiromi},
title = {Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29143379}
}
EUVIMED